Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2020

01-12-2020 | Osteoarthrosis | Research article

Proteoglycan-4 regulates fibroblast to myofibroblast transition and expression of fibrotic genes in the synovium

Authors: Marwa Qadri, Gregory D. Jay, Ling X. Zhang, Holly Richendrfer, Tannin A. Schmidt, Khaled A. Elsaid

Published in: Arthritis Research & Therapy | Issue 1/2020

Login to get access

Abstract

Background

Synovial tissue fibrosis is common in advanced OA with features including the presence of stress fiber-positive myofibroblasts and deposition of cross-linked collagen type-I. Proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and is a major component of synovial fluid. PRG4 is a ligand of the CD44 receptor. Our objective was to examine the role of PRG4-CD44 interaction in regulating synovial tissue fibrosis in vitro and in vivo.

Methods

OA synoviocytes were treated with TGF-β ± PRG4 for 24 h and α-SMA content was determined using immunofluorescence. Rhodamine-labeled rhPRG4 was incubated with OA synoviocytes ± anti-CD44 or isotype control antibodies and cellular uptake of rhPRG4 was determined following a 30-min incubation and α-SMA expression following a 24-h incubation. HEK-TGF-β cells were treated with TGF-β ± rhPRG4 and Smad3 phosphorylation was determined using immunofluorescence and TGF-β/Smad pathway activation was determined colorimetrically. We probed for stress fibers and focal adhesions (FAs) in TGF-β-treated murine fibroblasts and fibroblast migration was quantified ± rhPRG4. Synovial expression of fibrotic markers: α-SMA, collagen type-I, and PLOD2 in Prg4 gene-trap (Prg4GT) and recombined Prg4GTR animals were studied at 2 and 9 months of age. Synovial expression of α-SMA and PLOD2 was determined in 2-month-old Prg4GT/GT&Cd44−/− and Prg4GTR/GTR&Cd44−/− animals.

Results

PRG4 reduced α-SMA content in OA synoviocytes (p < 0.001). rhPRG4 was internalized by OA synoviocytes via CD44 and CD44 neutralization attenuated rhPRG4’s antifibrotic effect (p < 0.05). rhPRG4 reduced pSmad3 signal in HEK-TGF-β cells (p < 0.001) and TGF-β/Smad pathway activation (p < 0.001). rhPRG4 reduced the number of stress fiber-positive myofibroblasts, FAs mean size, and cell migration in TGF-β-treated NIH3T3 fibroblasts (p < 0.05). rhPRG4 inhibited fibroblast migration in a macrophage and fibroblast co-culture model without altering active or total TGF-β levels. Synovial tissues of 9-month-old Prg4GT/GT animals had higher α-SMA, collagen type-I, and PLOD2 (p < 0.001) content and Prg4 re-expression reduced these markers (p < 0.01). Prg4 re-expression also reduced α-SMA and PLOD2 staining in CD44-deficient mice.

Conclusion

PRG4 is an endogenous antifibrotic modulator in the joint and its effect on myofibroblast formation is partially mediated by CD44, but CD44 is not required to demonstrate an antifibrotic effect in vivo.
Literature
1.
2.
Cross M, Smith E, Hoy D, Nolte S, Ackerman I, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann rheum Dis. 2014;73(7):1323–30.PubMed
3.
Fu K, Robbins SR, JJ MD. Osteoarthritis: the genesis of pain. Rheumatology (Oxford). 2018;57(suppl_4):iv43–50.
4.
5.
Cleveland RJ, Alvarez C, Schwartz TA, Losina E, Renner JB, et al. The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up. Osteoarthritis Cartilage. 2019;27(4):593–602.PubMed
6.
Veronnese N, Cereda E, Maggi S, Luchini C, Solmi M, et al. Osteoarthritis and mortality: a prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016;46(2):160–7.
7.
O’Neill TW, PS MC, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol. 2018;32(2):312–26.PubMed
8.
Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, et al. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(4):507–15.PubMed
9.
Carbone A, Rodeo S. Review of current understanding of post-traumatic osteoarthritis resulting from sports injuries. J Orthop Res. 2017;35(3):397–405.PubMed
10.
Poulsen E, Goncalves GH, Bicca A, Roos EM, Thorlund JB, et al. Knee osteoarthritis risk is increased 4-6 fold after knee injury-a systematic review and meta-analysis. Br J Sports Med. 2019;53(23):1454–63.PubMed
11.
12.
Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.PubMed
13.
14.
Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19:18.PubMedPubMedCentral
15.
Guermazi A, Hayashi D, Roemer FW, Zhu Y, Niu J, et al. Synovitis in knee osteoarthritis assessed by contrast-enhanced magnetic resonance imaging (MRI) is associated with radiographic tibiofemoral osteoarthritis and MRI-detected widespread cartilage damage: the MOST study. J Rheumatol. 2014;41(3):501–8.PubMedPubMedCentral
16.
Baker K, Grainger A, Niu J, Clancy M, Guermazi A, et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis. 2010;69(1):1779–83.PubMed
17.
Gomez R, Villavilla A, Largo R, Gualillo O, Herrero-Beaumont G. TLR4 signaling in osteoarthritis-finding targets for candidate DMOADs. Nat Rev Rheumatol. 2015;11:159–70.PubMed
18.
Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008;20:565–72.PubMed
19.
Sharma N, Drobinski P, Kayed A, Chen Z, Kjelgaard-Petersen CF, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2019. https://​doi.​org/​10.​1016/​j.​joca.​2019.​11.​002 [Epub ahead of print].
20.
Herrero-Beaumont G, Perez-Baos S, Sanchez-Pernaute O, Roman-Blas JA, Lamuedra A, et al. Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. Biochem Pharmacol. 2019;165:24–32.PubMed
21.
Kalaitzoglou E, Griffin TM, Humphrey MB. Innate immune responses and osteoarthritis. Curr Rheumatol Rep. 2017;19(8):45.PubMed
22.
Conaghan PG, D’Agostino MA, Le Bars M, Schmidely N, Wakefield R, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010;69(4):644–7.PubMed
23.
Wang X, Hunter DJ, Ding C. The importance of synovial inflammation in osteoarthritis: current evidence from imaging assessments and clinical trials. Osteoarthritis Cartilage. 2018;26(2):165–74.PubMed
24.
Collins JE, Losina E, Nevitt MC, Roermer FW, Guermazi A, et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium. Arthritis Rheumatol. 2016;68(10):2422–31.PubMedPubMedCentral
25.
Atukorala I, Kwoh CK, Guermazi A, Roemer FW, Boudreau RM, et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheum Dis. 2016;75(2):390–5.PubMed
26.
Henrotin Y, Pesesse L, Lambert C. Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Ther Adv Musculoskelet Dis. 2014;6(1):20–34.PubMedPubMedCentral
27.
Benito M, Veale D, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263–7.PubMedPubMedCentral
28.
Smith MD. The normal synovium. Open Rheumatol J. 2015;5:100–6.
29.
Jay GD, Waller KA. The biology of lubricin: near frictionless joint motion. Matrix Biol. 2014;39:17–24.PubMed
30.
Jay GD, Britt DE, Cha CJ. Lubricin is a product of megakaryocyte stimulating factor gene expression by human synovial fibroblasts. J Rheumatol. 2000;27:594–600.PubMed
31.
Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 2005;52(11):3492–501.PubMed
32.
Abdul N, Dixon D, Walker A, Horabin J, Smith N, et al. Fibrosis is a common outcome following total knee arthroplasty. Sci Rep. 2015;5:16469.PubMedPubMedCentral
33.
Remst DF, Blaney Davidson EN, Vitters EL, Blom AB, Stoop R, et al. Osteoarthritis-related fibrosis is associated with both elevated pyrdinoline cross-link formation and lysyl hydroxylase 2b expression. Osteoarthritis Cartilage. 2013;21:157–64.PubMed
34.
Remst DF, Blom AB, Vitters EL, Bank RA, van den Berg WB, et al. Gene expression analysis of murine and human osteoarthritis synovium reveals elevation of transforming growth factor β-responsive genes in osteoarthritis-related fibrosis. Arthritis Rheumatol. 2014;66:647–56.PubMed
35.
van der Kraan PM. The changing role of TGFβ in healthy, aging and osteoarthritic joints. Nat Rev Rheumatol. 2017;13:155–63.PubMed
36.
Remst DF, Blaney Davidson EN, Vitters EL, Bank RA, van den Berg WB, et al. TGF-β induces lysyl hydroxylase 2b in human synovial osteoarthritic fibroblasts through ALK5 signaling. Cell Tissue Res. 2014;355:163–71.PubMed
37.
Bong MR, Di Cesare PE. Stiffness after total knee arthroplasty. J Am Acad Orthop Surg. 2004;12(3):f–71.
38.
Qadri MM, Jay GD, Ostrom RS, Zhang LX, Elsaid KA. cAMP attenuates TGF-β’s profibrotic responses in osteoarthritic synoviocytes: involvement of hyaluronan and PRG4. Am J Physiol Cell Physiol. 2018;315:C432–43.PubMedPubMedCentral
39.
Al-Sharif A, Jamal M, Zhang LX, Larson K, Schmidt TA, et al. Lubricin/proteoglycan 4 binding to CD44 receptor: a mechanism of the suppression of proinflammatory cytokine-induced synoviocyte proliferation by lubricin. Arthritis Rheumatol. 2015;67:1503–13.PubMedPubMedCentral
40.
Alquraini A, Jamal M, Zhang L, Schmidt T, Jay GD, et al. The autocrine role of proteoglycan-4 (PRG4) in modulating osteoarthritic synoviocyte proliferation and expression of matrix degrading enzymes. Arthritis res Ther. 2017;19:89.PubMedPubMedCentral
41.
Neumann E, Riepl B, Knedla A, Lefevre S, Tarner IH, et al. Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 2010;12:R83.PubMedPubMedCentral
42.
Jay GD, Fleming BC, Watkins BA, KA MH, Anderson SC, et al. Prevention of cartilage degeneration and restoration of chondroprotection by lubricin tribosupplementation in the rat following anterior cruciate ligament transection. Arthritis Rheum. 2010;62:2382–91.PubMedPubMedCentral
43.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.
44.
Samson ML, Morrison S, Masala N, Sullivan BD, Sullivan DA, et al. Characterization of full-length recombinant human proteoglycan 4 as an ocular surface boundary lubricant. Exp Eye Res. 2014;127C:14–9.
45.
Acharya PS, Majumdar S, Jacob M, Hayden J, Mrass P, et al. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J Cell Sci. 2008;121:1393–402.PubMed
46.
Ascione F, Vasaturo A, Caserta S, D’Esposito V, Formisano P, et al. Comparison between fibroblast wound healing and cell random migration assays in vitro. Exp Cell Res. 2016;347:123–32.PubMed
47.
Rhee DK, Marcelino J, Baker M, Gong Y, Smits P, Lefebvre V, et al. The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest. 2005;115:622–31.PubMedPubMedCentral
48.
Hill A, Walker KA, Cui Y, Allen JM, Smits P, et al. Lubricin restoration in a mouse model of congenital deficiency. Arthritis Rheumatol. 205;67:3070–81.
49.
Protin U, Schweighoffer T, Jochum W, Hilberg F. CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol. 1999;163:4917–23.PubMed
50.
Swann DA, Silver FH, Slayter HS, Stafford W, Shore E. The molecular structure and lubricating activity of lubricin isolated from bovine and human synovial fluids. Biochem J. 1985;225(1):195–201.PubMedPubMedCentral
51.
Jay GD, Habertstroh K, Cha CJ. Comparison of the boundary lubricating ability of bovine synovial fluid, lubricin, and Healon. J Biomed Mater Res. 1998;49(3):414–8.
52.
Jay GD, Tantravahi U, Britt DE, Barrach HJ, Cha CJ. Homology of lubricin and superficial zone protein (SZP): products of megakaryocyte stimulating factor (MSF) gene expression by human synovial fibroblasts and articular chondrocytes localized to chromosome 1q25. J Orthop Res. 2001;19(4):677–87.PubMed
53.
Flannery CR, Hughes CE, Schumacher BL, Tudor D, Aydelotte MB, et al. Articular cartilage superficial zone protein (SZP) is homologous to megakaryocyte stimulating factor precursor and is a multifunctional proteoglycan with potential growth-promoting cytoprotective, and lubricating properties in cartilage metabolism. Biochem Biophys Res Commun. 1999;254(3):535–41.PubMed
54.
Schmidt TA, Gastelum NS, Nguyen QT, Schumacher BL, Sah RL. Boundary lubrication of articular cartilage: role of synovial fluid constituents. Arthritis Rheum. 2007;56(3):882–91.PubMed
55.
Waller KA, Zhang LX, Jay GD. Friction-induced mitochondrial dysregulation contributes to joint deterioration in Prg4 knockout mice. Int J Mol Sci. 2017;18(6):E1252.
56.
Larson KM, Zhang L, Badger GJ, Jay GD. Early genetic restoration of lubricin expression in transgenic mice mitigates chondrocyte peroxynitrite release and caspase-3 activation. Osteoarthritis Cartilage. 2017;25(9):1488–95.PubMedPubMedCentral
57.
Elsaid KA, Machan JT, Waller K, Fleming BC, Jay GD. The impact of anterior cruciate ligament injury on lubricin metabolism and the effect of inhibiting tumor necrosis factor alpha on chondroprotection in an animal model. Arthritis Rheum. 2009;60(10):2997–3006.PubMedPubMedCentral
58.
Schmidt TA, Gastelum NS, Han EH, Nugent-Derfus GE, Schumacher BL, et al. Differential regulation of proteoglycan 4 metabolism in cartilage by IL-1 alpha, IGF-1, and TGF-beta 1. Osteoarthritis Cartilage. 2008;16(1):90–7.PubMed
59.
Blewis ME, Lao BJ, Schumacher BL, Bugbee WD, Sah RL, et al. Interactive cytokine regulation of synoviocyte lubricant secretion. Tissue Eng Part A. 2010;16(4):1329–37.PubMed
60.
Elsaid KA, Fleming BC, Oskendahl HL, Machan JT, Fadale PD, et al. Decreased lubricin concentrations and markers of joint inflammation in the synovial fluid of patients with anterior cruciate ligament injury. Arthritis Rheum. 2008;58(6):1707–15.PubMedPubMedCentral
61.
Catterall JB, Stabler TV, Flannery CR, Kraus VB. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther. 2010;12(6):R229.PubMedPubMedCentral
62.
Kosinska MK, Ludwig TE, Liebisch G, Zhang R, Siebert HC, et al. Articular joint lubricants during osteoarthritis and rheumatoid arthritis display altered levels and molecular species. PLoS One. 2015;10:e0125192.PubMedPubMedCentral
63.
Elsaid KA, Zhang L, Waller K, Tofte J, Teeple E, et al. The impact of forced joint exercise on lubricin biosynthesis from articular cartilage following ACL transection and intra-articular lubricin’s effect in exercised joints following ACL transection. Osteoarthritis Cartilage. 2012;20:940–8.PubMed
64.
Cui Z, Xu C, Li X, Song J, Yu B. Treatment with recombinant lubricin attenuates osteoarthritis by positive feedback loop between articular cartilage and subchondral bone in ovariectomized rats. Bone. 2015;74:37–47.PubMed
65.
Waller KA, Chin KE, Jay GD, Zhang LX, Teeple E, et al. Intra-articular recombinant human proteoglycan-4 mitigates cartilage damage after destabilization of the medial meniscus in the Yucatan minipig. Am J Sports Med. 2017;45(7):1512–21.PubMedPubMedCentral
66.
Cutly M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol. 1992;116(4):1055–62.
67.
Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103(Pt 2):293–8.PubMed
68.
Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509–12.PubMed
69.
Senbanjo LT, Chellaiah M. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18.PubMedPubMedCentral
70.
Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.PubMedPubMedCentral
71.
Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front. Immunol. 2015;6:201.PubMedPubMedCentral
72.
Mellor L, Knudson CB, Hida D, Askew EB, Knudson W. Intracellular domain fragment of CD44 alters CD44 function in chondrocytes. J Biol Chem. 2013;288(36):25838–50.PubMedPubMedCentral
73.
Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1 beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516–25.PubMed
74.
Yatabe T, Mochizuki S, Takizawa M, Chijiwa M, Okada A, et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanases-1) in human osteoarthritic chondrocytes. Ann Rheum Dis. 2009;68(6):1051–8.PubMedPubMedCentral
75.
Kataoka Y, Ariyoshi W, Okinaga T, Kaneuki T, Mitsugi S, et al. Mechanisms involved in suppression of ADAMTS4 expression in synoviocytes by high molecular weight hyaluronic acid. Biochem Biophys Res Commun. 2013;432(4):580–5.PubMed
76.
Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1 beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. 2007;465:241–8.PubMed
77.
Plaas A, Li J, Riesco J, Das R, Sandy JD, et al. Intrarticular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. Arthritis Res Ther. 2011;13:R46.PubMedPubMedCentral
78.
Alquraini A, Garguilo S, D’Souza G, Zhang LX, Schmidt TA, et al. The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther. 2015;17:353.PubMedPubMedCentral
79.
Iqbal SM, Leonard C, Regmi SC, De Rantere D, Tailor P, et al. Lubricin/proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep. 2016;6:18910.PubMedPubMedCentral
80.
Qadri M, Jay GD, Zhang LX, Wong W, Reginato M, et al. Recombinant human proteoglycan-4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of cytokines and chemokines in human and murine macrophages. Arthritis Res Ther. 2018;20(1):192.PubMedPubMedCentral
81.
Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–40.PubMedPubMedCentral
82.
Sarini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 1999;250:273–83.
83.
Ehrlich HP, Allison GM, Leggett M. The myofibroblast, cadherin, alpha smooth muscle actin and the collagen effect. Cell Biochem Funct. 2006;24:63–70.PubMed
84.
Livne A, Geiger B. The inner workings of stress fibers-from contractile machinery to focal adhesions and back. J Cell Sci. 2016;129(7):1293–304.PubMed
85.
86.
Steenvoorden MM, Tolboom TC, van der Pluijm G, Löwik C, Visser CP, et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther. 2006;8:R165.PubMedPubMedCentral
87.
Zappone B, Ruths M, Greene GW, Jay GD, Israelachvili JN. Adsorption, lubrication, and wear of lubricin on model surfaces: polymer brush-like behavior of a glycoprotein. Biophys J. 2007;92(5):1693–708.PubMed
88.
Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol. 2010;42(4):535–42.PubMed
89.
Reikoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol. 2011;11(6):427–35.
90.
91.
Bosch U, Zeichen J, Skutek M, Haeder L, van Griensven M. Arthrofibrosis is the result of a T cell mediated immune response. Knee Surg Sports Traumatol Arthrosc. 2001;9(5):282–9.PubMed
92.
Freeman TA, Parvizi J, Della Valle CJ, Steinbeck MJ. Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair. 2009;2(1):5.PubMedPubMedCentral
93.
Wermuth PJ, Jiminez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med. 2015;4:2.PubMedPubMedCentral
94.
Donlin LT, Jayatilleke A, Giannopoulou EG, Kalliolias GD, Ivashkiv LB. Modulation of TNF-induced macrophage polarization by synovial fibroblasts. J Immunol. 2014;193(5):23773–2383.
95.
Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factor. 2011;29(5):196–202.
96.
Stone A, Grol MW, Ruan MZC, Dawson B, Chen Y, et al. Combinatorial Prg4 and IL-1ra gene therapy protects against hyperalgesia and cartilage degeneration in post-traumatic osteoarthritis. Human Gene Ther. 2019;30(2):225–35.
97.
Ruan MZ, Erez A, Guse K, Dawson B, Bertin T, et al. Proteoglycan 4 expression protects against the development of osteoarthritis. Sci Transl Med. 2013;5(176):176ra34.PubMedPubMedCentral
Metadata
Title
Proteoglycan-4 regulates fibroblast to myofibroblast transition and expression of fibrotic genes in the synovium
Authors
Marwa Qadri
Gregory D. Jay
Ling X. Zhang
Holly Richendrfer
Tannin A. Schmidt
Khaled A. Elsaid
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2020
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-020-02207-x

Other articles of this Issue 1/2020

Arthritis Research & Therapy 1/2020 Go to the issue

Research article

The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

Research article

Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication

Research article

Development of a multivariable improvement measure for gout

Research article

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Research article

Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort

Research article

The first composite score predicting Digital Ulcers in systemic sclerosis patients using Clinical data, Imaging and Patient history—CIP-DUS
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits